OnabotulinumtoxinA (BOTOX ®): A review of its use in the prophylaxis of headaches in adults with chronic migraine

Drugs

Volumn 72, Issue 6, 2012, Pages 825-845

  Frampton, James E ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Botulinum toxin A; Headache; Migraine

Indexed keywords

BOTULINUM TOXIN A; TOPIRAMATE;

DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; HEADACHE; HUMAN; INJECTION SITE PAIN; MIGRAINE; MULTIPLE CYCLE TREATMENT; MUSCLE TIGHTNESS; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; MUSCULOSKELETAL STIFFNESS; MYALGIA; NAUSEA; NECK PAIN; PTOSIS; RECOMMENDED DRUG DOSE; REVIEW; TRANSFORMED MIGRAINE;

ADULT; BOTULINUM TOXINS, TYPE A; HEADACHE; HUMANS; MIGRAINE DISORDERS; NEUROMUSCULAR AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84859925126     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11208880-000000000-00000     Document Type: Review

References (97)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med 2002 Jan 24; 346 (4): 257-70
2. D'Andrea G, Colavito D, Dalle Carbonare M, et al.Migraine with aura: conventional and non-conventional treatments. Neurol Sci 2011May; 32 Suppl. 1: S121-129
3. Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005; 45 Suppl. 1: S3-13 (Pubitemid 40532985)
4. Buse DC, Rupnow MFT, Lipton BB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 2009; 84 (5): 422-35
5. Burton WN, Landy SH, Downs KE, et al. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin Proc 2009; 84 (5): 436-45
6. Lipton RB. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache 2011; 51 Suppl. 2: 77-83
7. Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep 2011 Feb; 15 (1): 70-8
8. Manack A, Turkel C, Silberstein S. The evolution of chronic migraine: classification and nomenclature. Headache 2009; 49: 1206-13
9. Oleson J, Bousser M-G, Diener H-C, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742-6
10. Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep 2009 Aug; 13 (4): 301-7
11. Tepper SJ, Tepper DE. Breaking the cycle of medication overuse headache. Cleve Clin J Med 2010 Apr; 77 (4): 236-42
12. Bigal M, Rapoport A, Sheftell F, et al. The International Classification of Headache Disorders revised criteria for chronic migraine-field testing in a headache specialty clinic. Cephalalgia 2007; 27: 230-4 (Pubitemid 46354124)
13. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalagia 2010; 30 (5): 599-609
14. Bigal ME, Rapoport AM, Lipton RB, et al. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache 2003 Apr; 43 (4): 336-42 (Pubitemid 36417763)
15. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011; 31 (3): 301-15
16. Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache 2001 Jun; 41 (6): 573-8 (Pubitemid 32619261)
17. Buse DC, Manack A, Serrano D, et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 2010; 81: 428-32
18. Ferrari A, Leone S, Vergoni AV, et al. Similarities and differences between chronic migraine and episodic migraine. Headache 2007; 47: 65-72 (Pubitemid 46096059)
19. Munakata J, Hazard E, Serrano D, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2009 Apr; 49 (4): 498-508
20. Thakker MM, Rubin PAD. Pharmacology and clinical applications of botulinum toxins A and B. Int Ophthalmol Clin 2004; 44 (3): 147-63 (Pubitemid 38955667)
21. Verheyden J, Blitzer A, Brin MF. Other noncosmetic uses of BOTOX. Semin Cutan Med Surg 2001 Jun; 20 (2): 121-6 (Pubitemid 32661745)
22. Schulte-Mattler WJ. Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety. CNS Drugs 2008; 22 (9): 725-38
23. Brin MF. Development of future indications for BOTOX. Toxicon 2009 Oct; 54 (5): 668-74
24. BOTOX 100 units: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/112/SPC/ BOTOX+100+units/[Accessed 2011 Nov 1]
25. BOTOX 50 units: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/20564/SPC/BOTOX+50+units/ [Accessed 2011 Nov 1]
26. BOTOX 200 units: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org. uk/EMC/medicine/22562/SPC/ Botox+200+units/[Accessed 2011 Nov 1]
27. Vistabel: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/17580/SPC/Vistabel/[Accessed 2011 Nov 16]
28. BOTOX (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use: US prescribing information [online]. Available from URL: http://www.allergan.com/assets/pdf/botox-pi.pdf [Accessed 2011 Nov 2]
29. BOTOX-Cosmetic (onabotulinumtoxinA) for injection: US prescribing information [online]. Available from URL: http://www.allergan.com/assets/pdf/ botox-cosmetic-pi.pdf [Accessed 2011 Nov 16]
30. Blumenfeld A, Silberstein SD, Dodick DW, et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 2010; 50 (9): 1406-18
31. Frampton JE, Easthope SE. Botulinum toxin A (Botox cosmetic): a review of its use in the treatment of glabellar frown lines. Am J Clin Dermatol 2003; 4 (10): 709-25 (Pubitemid 37411986)
32. Aoki KR. Pharmacology and immunology of botulinum neurotoxins. Int Ophthalmol Clin 2005; 45 (3): 25-37 (Pubitemid 41022173)
33. Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 2002 Nov; 27 (11): 552-8 (Pubitemid 35335403)
34. Dressler D, Adib Saheri F, Reis Barbosa E. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 2005; 63 (1): 180-5 (Pubitemid 40543441)
35. Wollina U. Botulinum toxin: non-cosmetic indications and possible mechanisms of action. J Cutan Aesthet Surg 2008 Jan; 1 (1): 3-6
36. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicol 2005 Oct; 26 (5): 785-93 (Pubitemid 41427518)
37. Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat D 2011 Nov; 17 Suppl. 1: S28-33
38. Pavone F, Luvisetto S. Botulinum neurotoxin for pain management: insights from animal models. Toxins 2010; 2: 2890-913
39. Durham PL, Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache 2011 Nov 14; 51 (10): 1573-7
40. Malik A, Burstein R. Peripheral and central sensitization during migraine. Funct Neurol 2000; 15 Suppl.: 28-35 (Pubitemid 32051372)
41. Mathew NT. Pathophysiology of chronic migraine and mode of action of preventive medications. Headache 2011; 51 Suppl. 2: 84-92
42. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003; 43 Suppl. 1: S9-15 (Pubitemid 36988542)
43. Kulthia AS, Barrodale PM, Turkel CC, et al. To study the effect of prophylaxis with onabotulinumtoxinA on the pain free response to 100 mg of sumatriptan in a group of chronic migraine patients [abstract no. P136]. 53rd Annual Scientific Meeting of the American Headache Society; 2011 Jun 2-5; Washington, DC
44. Naumann M, Carruthers A, Carruthers J, et al. Metaanalysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX-) across multiple indications. Mov Disord 2010 Oct 15; 25 (13): 2211-8
45. Medicines and Healthcare Products Regulatory Agency. Botox (Botulinum toxin type A): PL 00426/0074-0105; PL 00426/0118-0025; PL 00426/0119-0007: UKPAR [online]. Available from URL: http://www.mhra.gov.uk/home/groups/par/documents/ websiteresources/con108643.pdf [Accessed 2011 Oct 28]
46. Allergan. A study using botulinum toxin type A as headache prophylaxis for migraine patients with frequent headaches [ClinicalTrials.gov identifier NCT00156910]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Nov 2]
47. Allergan. A study using botulinum toxin type A as headache prophylaxis for migraine patients with frequent headaches [ClinicalTrials.gov identifier NCT00168428]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Nov 2]
48. Aurora S, Dodick D, Turkel C, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the doubleblind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30 (7): 793-803
49. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30 (7): 804-14
50. Dodick DW, Turkel CC, Degryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebocontrolled phases of the PREEMPT clinical program. Headache 2010; 50 (6): 921-36
51. Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011; 51: 1358-73
52. Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 2011 Oct 11; 77 (15): 1465-72
53. Aurora SK, Mathew NT, Forner SD, et al. OnabotulinumtoxinA for treatment of chronic migraine: analysis of the 56-week PREEMPT 1 trial [abstract no. P06.250]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10-17; Toronto (ON)
54. Dodick DW, Gawel MJ, Agosti RM, et al. OnabotulinumtoxinA for treatment of chronic migraine: analysis of the 56-week PREEMPT 2 trial [abstract no. P06.251]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10-17; Toronto (ON)
55. Therapeutic Goods Administration. Australian public assessment report for botulinum toxin type A [online]. Available from URL: http://www.tga.gov.au/pdf/ auspar/auspar-botox.pdf [Accessed 2011 Dec 2]
56. Mathew NT, Frishberg BM, Gawel M, et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005; 45 (4): 293-307 (Pubitemid 40530193)
57. Silberstein SD, Stark SR, Lucas SM. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2008; 80 (9): 1126-37
58. Mathew NT, Jaffri SFA. A double-blind comparison of onabotulinumtoxinA (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache 2009; 49 (10): 1466-78
59. Cady RK, Schreiber CP, Porter JAH, et al. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache 2011; 51 (1): 21-32
60. Coeytaux RR, Kaufman JS, Chao R, et al. Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. J Clin Epidemiol 2006; 59: 374-80
61. Dodick DW, Silberstein S, Saper J, et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache 2007; 47: 1398-408 (Pubitemid 350209536)
62. Markert RJ, Solomon GD. OnabotulinumtoxinA for treatment of chronic migraine. Headache 2011; 51 (6): 1002-3
63. Modi S, Lowder DM. Medications for migraine prophylaxis. Am Fam Phys 2006 Jan 1; 73 (1): 72-8 (Pubitemid 43161246)
64. Shü rks M, Diener HC, Goadsby P, et al. Update on the prophylaxis of migraine. Curr Treat Options Neurol 2008; 10 (1): 20-9
65. Fenstermacher N, Levin M, Ward T. Pharmacological prevention of migraine. BMJ 2011; 342 (7796): 540-3
66. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine: revised report of an EFNS task force. Eur J Neurol 2009; 16: 968-81
67. Antonachi F, Dumitrache C, De Cillis I, et al. A review of European treatment guidelines for migraine. J Headache Pain 2010 Feb; 11 (1): 13-9
68. Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ 2010; 182 (7): E269-276
69. Garza I, Swanson JW. Prophylaxis of migraine. Neuropsychiatr Dis Treat 2006; 2: 281-91 (Pubitemid 44566705)
70. British Association for the Study of Headache. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type headache, cluster headache and medication-overuse headache: 3rd edition (1st revision) [online]. Available from URL: http://217.174.249. 183/upload/NS-BASH/2010-BASH-guidelines.pdf [Accessed 2012 Feb 22]
71. Silvestri M, Bartolini M, Coccia M, et al. Topiramate in the treatment of chronic migraine. Expert Opin Pharmacother 2006; 7: 1085-95
72. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 170-80
73. North East Treatment Advisory Group. Botulinum toxin (Botox-) for chronic migraine [online]. Available from URL: http://www.nyrdtc.nhs.uk/docs/eva/ Botox%20for% 20chronic%20migraine%20-%20NETAG%20appraisal% 20report%20- Sept%202011-%20WEB%20VERSION.pdf [Accessed 2011 Dec 3]
74. Parsekyan D. Migraine prophylaxis in adult patients. West J Med 2000 Nov; 173 (5): 341-5
75. Vargas BB, Dodick DW. The face of chronic migraine: epidemiology, demographics, and treatment strategies. Neurol Clin 2009; 27: 467-79
76. Reed KL, Black SB, Banta II CJ, et al. Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience. Cephalalgia 2010; 30 (3): 260-71
77. Weibelt S, Andress-Rothrock D, King W, et al. Suboccipital nerve blocks for suppression of chronic migraine: safety, efficacy, and predictors of outcome. Headache 2010; 50: 1041-4
78. Mauskop A. Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalalgia 2005; 25: 82-6 (Pubitemid 40193950)
79. Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008; 71: 559-66
80. Dodick DW, Turkel CC, Degryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: a response. Headache 2011; 51 (6): 1005-8
81. Olesen J, Tfelt-Hansen P. Licence for Botox in so-called chronic migraine. Lancet 2010; 376 (9755): 1825-6
82. Torgovnick J. OnabotulinumtoxinA for the treatment of chronic migraine not quite there. Cephalalgia 2011; 31 (3): 377
83. Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008; 28: 484-95 (Pubitemid 351502554)
84. Aurora S, Diener HC, Dodick D. Reply: clinical trials on onabotulinumtoxinA for the treatment of chronic migraine. J Headache Pain 2011; 12 (2): 137-8
85. Russell MB. Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine. J Headache Pain 2011; 12 (2): 135-6
86. Freitag FG, Diamond S, Diamond M, et al. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 2008 Feb; 48 (2): 201-9 (Pubitemid 351192876)
87. Burstein R, Cutrer MF, Yarnitsky MF. The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000; 123: 1703-9 (Pubitemid 30481193)
88. Mathew P, Cutrer FM, Garza I. Cutaneous allodynia as a prognostic factor in the treatment of migraine with Botulinum toxin [abstract no. PO-69]. 52nd Annual Scientific Meeting of the American Headache Society; 2010 Jun 24-27; Los Angeles (CA)
89. Evers S, Olesen J. Botulinum toxin in headache treatment: the end of the road? Cephalalgia 2006; 26 (7): 769-71 (Pubitemid 43882984)
90. Naumann M, So Y, Argoff CE. for the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70 (19): 1707-14
91. Finkel AG. Botulinum toxin and the treatment of headache: a clinical review. Headache 2011; 51 (10): 1565-72
92. Schoenen J. Botulinum toxin in headache treatment: finally a promising path? Cephalalgia 2010; 30 (7): 771-3
93. Blumenfeld A, Evans RW. OnabotulinumtoxinA for chronic migraine. Headache. Epub 2012 Jan 23
94. Silberstein S, Dodick DW, Degryse RE, et al. The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program. 15th Congress of the European Federation of Neurological Societies; 2011 Sep 10-13; Budapest
95. Robertson CE, Garza I. Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine. Neuropsychiatr Dis Treat 2012; 8: 35-48
96. Scottish Medicines Consortium. Botulinum toxin type A, 50 unit, 100 unit and 200 unit powder for solution for injection. SMC No. (692/11) [online]. Available from URL: http://www.scottishmedicines.org.uk/files/advice/botulinum- toxin-type-A-Botox-FINAL-MARCH-2011-AMEND ED-22.03-for-website.pdf [Accessed 2011 Dec 3]
97. Rothrock J, Andress-Rothrock D, Hanlon C, et al. Is onabotulinumtoxinA a cost-effective therapy for chronic migraine? [abstract PS2-163]. 15th Congress of the International Headache Society; 2011 Jun 23-26; Berlin